| Dr Tehmina Khan, MD | |
|
953 49th St, Suite 511, Brooklyn, NY 11219-2923 | |
| (718) 273-8380 | |
| (718) 283-7884 |
| Full Name | Dr Tehmina Khan |
|---|---|
| Gender | Female |
| Speciality | Critical Care (intensivists) |
| Experience | 34 Years |
| Location | 953 49th St, Brooklyn, New York |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1013020197 | NPI | - | NPPES |
| 02717811 | Medicaid | NY |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RC0200X | Internal Medicine - Critical Care Medicine | P44504 (New York) | Primary |
| 207RP1001X | Internal Medicine - Pulmonary Disease | P44504 (New York) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Maimonides Medical Center | Brooklyn, NY | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Maimonides Medical Center-maimo Criticare Fpp | 3476441726 | 13 |
News Archive
If you are obese and hope to be a father, here's another reason to lose weight: your children and grandchildren may inherit your waistline or metabolic disorders. That's because scientists have discovered in mice that obese fathers, even those who did not show any signs of diabetes, passed this negative trait on most frequently to their daughters. Sons don't entirely dodge this genetic bullet either-both sons and daughters of obese fathers have increased risks of developing metabolic diseases, such as diabetes.
The College of American Pathologists (CAP), in collaboration with five other societies, developed a draft evidence-based clinical practice guideline that aims to optimize PD-L1 testing for patients with non-small cell lung cancer (NSCLC) who are being considered for immunooncology therapy.
Zafgen, a pharmaceutical company pioneering novel obesity therapeutics to help the body regain and sustain a lean, healthy state by targeting imbalances in fat metabolism, today announced positive topline results from its Phase 1b study of ZGN-433, a methionine aminopeptidase 2 inhibitor, for the treatment of severe obesity.
A pilot study has found that participating in a nine-week training program including elicitation of the relaxation response had a significant impact on clinical symptoms of the gastrointestinal disorders irritable bowel syndrome and inflammatory bowel disease and on the expression of genes related to inflammation and the body's response to stress.
Integrating some of the best new practices of industry into the strengths of the academic research process, the Regenstrief Institute is launching an initiative to encourage and propel innovation. The Institute has over 40 years of experience as an international leader in improving healthcare delivery.
› Verified 5 days ago
| Entity Name | Maimonides Medical Center-maimo Criticare Fpp |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1265547178 PECOS PAC ID: 3476441726 Enrollment ID: O20040308001234 |
News Archive
If you are obese and hope to be a father, here's another reason to lose weight: your children and grandchildren may inherit your waistline or metabolic disorders. That's because scientists have discovered in mice that obese fathers, even those who did not show any signs of diabetes, passed this negative trait on most frequently to their daughters. Sons don't entirely dodge this genetic bullet either-both sons and daughters of obese fathers have increased risks of developing metabolic diseases, such as diabetes.
The College of American Pathologists (CAP), in collaboration with five other societies, developed a draft evidence-based clinical practice guideline that aims to optimize PD-L1 testing for patients with non-small cell lung cancer (NSCLC) who are being considered for immunooncology therapy.
Zafgen, a pharmaceutical company pioneering novel obesity therapeutics to help the body regain and sustain a lean, healthy state by targeting imbalances in fat metabolism, today announced positive topline results from its Phase 1b study of ZGN-433, a methionine aminopeptidase 2 inhibitor, for the treatment of severe obesity.
A pilot study has found that participating in a nine-week training program including elicitation of the relaxation response had a significant impact on clinical symptoms of the gastrointestinal disorders irritable bowel syndrome and inflammatory bowel disease and on the expression of genes related to inflammation and the body's response to stress.
Integrating some of the best new practices of industry into the strengths of the academic research process, the Regenstrief Institute is launching an initiative to encourage and propel innovation. The Institute has over 40 years of experience as an international leader in improving healthcare delivery.
› Verified 5 days ago
| Entity Name | Maimonides Faculty Practice Plan |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1053344846 PECOS PAC ID: 7012808348 Enrollment ID: O20040324000597 |
News Archive
If you are obese and hope to be a father, here's another reason to lose weight: your children and grandchildren may inherit your waistline or metabolic disorders. That's because scientists have discovered in mice that obese fathers, even those who did not show any signs of diabetes, passed this negative trait on most frequently to their daughters. Sons don't entirely dodge this genetic bullet either-both sons and daughters of obese fathers have increased risks of developing metabolic diseases, such as diabetes.
The College of American Pathologists (CAP), in collaboration with five other societies, developed a draft evidence-based clinical practice guideline that aims to optimize PD-L1 testing for patients with non-small cell lung cancer (NSCLC) who are being considered for immunooncology therapy.
Zafgen, a pharmaceutical company pioneering novel obesity therapeutics to help the body regain and sustain a lean, healthy state by targeting imbalances in fat metabolism, today announced positive topline results from its Phase 1b study of ZGN-433, a methionine aminopeptidase 2 inhibitor, for the treatment of severe obesity.
A pilot study has found that participating in a nine-week training program including elicitation of the relaxation response had a significant impact on clinical symptoms of the gastrointestinal disorders irritable bowel syndrome and inflammatory bowel disease and on the expression of genes related to inflammation and the body's response to stress.
Integrating some of the best new practices of industry into the strengths of the academic research process, the Regenstrief Institute is launching an initiative to encourage and propel innovation. The Institute has over 40 years of experience as an international leader in improving healthcare delivery.
› Verified 5 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Tehmina Khan, MD 953 49th St, Suite 511, Brooklyn, NY 11219-2923 Ph: (718) 273-8380 | Dr Tehmina Khan, MD 953 49th St, Suite 511, Brooklyn, NY 11219-2923 Ph: (718) 273-8380 |
News Archive
If you are obese and hope to be a father, here's another reason to lose weight: your children and grandchildren may inherit your waistline or metabolic disorders. That's because scientists have discovered in mice that obese fathers, even those who did not show any signs of diabetes, passed this negative trait on most frequently to their daughters. Sons don't entirely dodge this genetic bullet either-both sons and daughters of obese fathers have increased risks of developing metabolic diseases, such as diabetes.
The College of American Pathologists (CAP), in collaboration with five other societies, developed a draft evidence-based clinical practice guideline that aims to optimize PD-L1 testing for patients with non-small cell lung cancer (NSCLC) who are being considered for immunooncology therapy.
Zafgen, a pharmaceutical company pioneering novel obesity therapeutics to help the body regain and sustain a lean, healthy state by targeting imbalances in fat metabolism, today announced positive topline results from its Phase 1b study of ZGN-433, a methionine aminopeptidase 2 inhibitor, for the treatment of severe obesity.
A pilot study has found that participating in a nine-week training program including elicitation of the relaxation response had a significant impact on clinical symptoms of the gastrointestinal disorders irritable bowel syndrome and inflammatory bowel disease and on the expression of genes related to inflammation and the body's response to stress.
Integrating some of the best new practices of industry into the strengths of the academic research process, the Regenstrief Institute is launching an initiative to encourage and propel innovation. The Institute has over 40 years of experience as an international leader in improving healthcare delivery.
› Verified 5 days ago
Dr. Alexander Usorov, MD Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 447 Atlantic Ave, Brooklyn, NY 11217 Phone: 718-858-6300 | |
Dr. Marcellus Andre Walker, MD Pulmonary Disease Medicare: May Accept Medicare Assignments Practice Location: 2094 Pitkin Ave, Brooklyn, NY 11207 Phone: 718-240-0516 Fax: 718-240-0564 | |
Lotus Ahmed, D.O Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 518 Mcdonald Ave, Brooklyn, NY 11218 Phone: 917-848-5432 Fax: 347-252-6754 | |
Mrs. Sophia Schwartzman, MD Pulmonary Disease Medicare: Not Enrolled in Medicare Practice Location: 2700 Ocean Avenue, Brooklyn, NY 11229 Phone: 518-587-1141 | |
Dr. Haitham M Ahmed, MD, MPH Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 101 Pennsylvania Avenue, Brooklyn, NY 11207 Phone: 718-240-2000 Fax: 718-240-2260 | |
Yanjin Yang, Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 506 6th St, Brooklyn, NY 11215 Phone: 718-780-3000 | |
Ashwad Afzal, M.D. Pulmonary Disease Medicare: Medicare Enrolled Practice Location: 506 6th St, Brooklyn, NY 11215 Phone: 718-780-5246 |